[{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$12.2 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer, Novo-backed German biotech banks \u20ac11M in liver regeneration push","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed"},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HepaRegeniX Publishes Data for Its First-In-Class MKK4 inhibitor HRX-215 for the treatment of Acute and Chronic Liver Diseases in Cell","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by HepaRegeniX
HRX-0215 is a small molecule inhibitor of MKK4, a key regulator of liver regeneration. It is being evaluated for the treatment of hepatic steatosis, liver damage & nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma.